Acute Stroke

Poli, Loris; Costa, Paolo; Morotti, Andrea

doi:10.1055/s-0038-1676992

Cited by 37 publications

(23 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 4 Currently, revascularization therapies including intravenous thrombolysis and endovascular thrombectomy remain the clinical approaches available for stroke patients. 5 However, a majority of stroke patients do not satisfy the criteria for thrombolysis and consequently, these patients tend to have residual neurological deficits. 1 It is well established that improving neurological functions by supporting neurogenesis contributes to reducing the chronic disability in stroke patients.…”

Section: Introductionmentioning

confidence: 99%

RETRACTED: Mechanism of ARPP21 antagonistic intron miR‐128 on neurological function repair after stroke

Chai

Zheng

2021

Ann Clin Transl Neurol

View full text Add to dashboard Cite

Objective: Stroke is a cerebrovascular disorder that often causes neurological function defects. ARPP21 is a conserved host gene of miR-128 controlling neurodevelopmental functions. This study investigated the mechanism of ARPP21 antagonistic intron miR-128 on neurological function repair after stroke. Methods: Expressions of ARPP21 and miR-128 in stroke patients were detected. The mouse neurons and astrocytes were cultured in vitro and treated with oxygenglucose deprivation (OGD). The OGD-treated cells were transfected with pc-ARPP21 and miR-128 mimic. The proliferation of astrocytes, and the apoptosis of neurons and astrocytes were detected, and inflammatory factors of astrocytes were measured. The binding relationship between miR-128 and CREB1 was verified. The rat model of middle cerebral artery occlusion (MCAO) was established. ARPP21 expression in model rats was detected. The effects of pc-ARPP21 on neuron injury, brain edema volume, and cerebral infarct in rats were observed. Results: ARPP21 expression was downregulated and miR-128 expression was upregulated in stroke patients. pc-ARPP21 facilitated the proliferation of astrocytes and inhibited apoptosis of neurons and astrocytes, and reduced inflammation of astrocytes. miR-128 mimic could reverse these effects of pc-ARPP21 on neurons and astrocytes. miR-128 targeted CREB1 and reduced BDNF secretion. In vitro experiments confirmed that ARPP21 expression was decreased in MCAO rats, and pc-ARPP21 promoted neurological function repair after stroke. Conclusion: ARPP21 upregulated CREB1 and BDNF expressions by antagonizing miR-128, thus inhibiting neuronal apoptosis and promoting neurological function repair after stroke. This study may offer a novel target for the management of stroke.

show abstract

Section: Introductionmentioning

confidence: 99%

RETRACTED: Mechanism of ARPP21 antagonistic intron miR‐128 on neurological function repair after stroke

Chai

Zheng

2021

Ann Clin Transl Neurol

View full text Add to dashboard Cite

show abstract

“…CT is sufficient to decide on thrombolysis in acute strokes within 4.5 h after the onset of the symptom. It remains the only mandatory radiological examination before IVT [12,13]. Noninvasive intracranial vascular imaging should also be performed in patients with suspected large vessel occlusion and who may require endovascular recanalization therapy, without delaying IV thrombolytic therapy [8,13].…”

Section: Neuroimaging In Acute Strokementioning

confidence: 99%

Thrombolysis in Acute Stroke

Çetiner¹

2022

Cerebrovascular Diseases - Elucidating Key Principles

View full text Add to dashboard Cite

The first step in stroke care is early detection of stroke patients and recanalization of the occluded vessel. Rapid and effective revascularization is the cornerstone of acute ischemic stroke management. Intravenous thrombolysis is the only approved pharmacological reperfusion therapy for patients with acute ischemic stroke. Patient selection criteria based on patient characteristics, time, clinical findings and advanced neuroimaging techniques have positively affected treatment outcomes. Recent studies show that the presence of salvageable brain tissue can extend the treatment window for intravenous thrombolysis and that these patients can be treated safely. Recent evidence provides stronger support for another thrombolytic agent, tenecteplase, as an alternative to alteplase. Endovascular thrombectomy is not a contraindication for intravenous thrombolysis. Evidence shows that the bridging approach provides better clinical outcomes. It is seen that intravenous thrombolysis is beneficial in stroke patients, whose symptom onset is not known, after the presence of penumbra tissue is revealed by advanced neuroimaging techniques. Reperfusion therapy with intravenous thrombolysis is beneficial in selected pregnant stroke patients. Pregnancy should not be an absolute contraindication for thrombolysis therapy. This chapter aims to review only the current evaluation of intravenous thrombolytic therapy, one of the reperfusion therapies applied in the acute phase of stroke.

show abstract

“…Acute stroke remains the leading cause of morbidity and mortality worldwide, 1 and is the main cause of disability. 2 Stroke results from transient or permanent cerebral ischemia caused by arterial stenosis or occlusion, and common manifestations of this disease are focal neurological deficits.…”

Section: Introductionmentioning

confidence: 99%

“…3,4 Intravenous thrombolysis and endovascular thrombectomy (EVT) are the 2 main treatments for revascularization. 1 Recent randomized clinical trials have shown that EVT has a strong therapeutic effect on acute ischemic stroke caused by large vessel occlusions. 5 However, damage to pig extracranial arteries, particularly endothelial cells, has been reported following EVT.…”

Section: Introductionmentioning

confidence: 99%